Tags

Type your tag names separated by a space and hit enter

Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial.
Phytomedicine. 2004 Jul; 11(5):375-82.P

Abstract

In order to compare the antihypertensive effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa with captopril, a controlled and randomized clinical trial was done. Patients from 30 to 80 years old with diagnosed hypertension and without antihypertensive treatment for at least 1 month before were included. The experimental procedure consisted of the administration of an infusion prepared with 10 g of dry calyx from H. sabdariffa on 0.51 water (9.6 mg anthocyanins content), daily before breakfast, or captopril 25 mg twice a day, for 4 weeks. The outcome variables were tolerability, therapeutic effectiveness (diastolic reduction > or = 10 mm Hg) and, in the experimental group, urinary electrolytes modification. Ninety subjects were included, 15 withdrew from the study due to non-medical reasons; so, the analysis included 39 and 36 patients from the experimental and control group, respectively. The results showed that H. sabdariffa was able to decrease the systolic blood pressure (BP) from 139.05 to 123.73mm Hg (ANOVA p < 0.03) and the diastolic BP from 90.81 to 79.52mm Hg (ANOVA p < 0.06). At the end of the study, there were no significant differences between the BP detected in both treatment groups (ANOVA p > 0.25). The rates of therapeutic effectiveness were 0.7895 and 0.8438 with H. sabdariffa and captopril, respectively (chi2, p > 0.560), whilst the tolerability was 100% for both treatments. A natriuretic effect was observed with the experimental treatment. The obtained data confirm that the H. sabdariffa extract, standardized on 9.6mg of total anthocyanins, and captopril 50 mg/day, did not show significant differences relative to hypotensive effect, antihypertensive effectiveness, and tolerability.

Authors+Show Affiliations

Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social, Argentina 1 Xochitepec, 62790 Morelos, Mexico. armandoha_mx@yahoo.com.mxNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15330492

Citation

Herrera-Arellano, A, et al. "Effectiveness and Tolerability of a Standardized Extract From Hibiscus Sabdariffa in Patients With Mild to Moderate Hypertension: a Controlled and Randomized Clinical Trial." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 11, no. 5, 2004, pp. 375-82.
Herrera-Arellano A, Flores-Romero S, Chávez-Soto MA, et al. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine. 2004;11(5):375-82.
Herrera-Arellano, A., Flores-Romero, S., Chávez-Soto, M. A., & Tortoriello, J. (2004). Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 11(5), 375-82.
Herrera-Arellano A, et al. Effectiveness and Tolerability of a Standardized Extract From Hibiscus Sabdariffa in Patients With Mild to Moderate Hypertension: a Controlled and Randomized Clinical Trial. Phytomedicine. 2004;11(5):375-82. PubMed PMID: 15330492.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. AU - Herrera-Arellano,A, AU - Flores-Romero,S, AU - Chávez-Soto,M A, AU - Tortoriello,J, PY - 2004/8/28/pubmed PY - 2004/9/17/medline PY - 2004/8/28/entrez SP - 375 EP - 82 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 11 IS - 5 N2 - In order to compare the antihypertensive effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa with captopril, a controlled and randomized clinical trial was done. Patients from 30 to 80 years old with diagnosed hypertension and without antihypertensive treatment for at least 1 month before were included. The experimental procedure consisted of the administration of an infusion prepared with 10 g of dry calyx from H. sabdariffa on 0.51 water (9.6 mg anthocyanins content), daily before breakfast, or captopril 25 mg twice a day, for 4 weeks. The outcome variables were tolerability, therapeutic effectiveness (diastolic reduction > or = 10 mm Hg) and, in the experimental group, urinary electrolytes modification. Ninety subjects were included, 15 withdrew from the study due to non-medical reasons; so, the analysis included 39 and 36 patients from the experimental and control group, respectively. The results showed that H. sabdariffa was able to decrease the systolic blood pressure (BP) from 139.05 to 123.73mm Hg (ANOVA p < 0.03) and the diastolic BP from 90.81 to 79.52mm Hg (ANOVA p < 0.06). At the end of the study, there were no significant differences between the BP detected in both treatment groups (ANOVA p > 0.25). The rates of therapeutic effectiveness were 0.7895 and 0.8438 with H. sabdariffa and captopril, respectively (chi2, p > 0.560), whilst the tolerability was 100% for both treatments. A natriuretic effect was observed with the experimental treatment. The obtained data confirm that the H. sabdariffa extract, standardized on 9.6mg of total anthocyanins, and captopril 50 mg/day, did not show significant differences relative to hypotensive effect, antihypertensive effectiveness, and tolerability. SN - 0944-7113 UR - https://www.unboundmedicine.com/medline/citation/15330492/Effectiveness_and_tolerability_of_a_standardized_extract_from_Hibiscus_sabdariffa_in_patients_with_mild_to_moderate_hypertension:_a_controlled_and_randomized_clinical_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0944-7113(04)00002-9 DB - PRIME DP - Unbound Medicine ER -